Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$13.18 -2.7%	$13.84	$10.57 ▼ $33.33	$1.92B	1.49	1.11 million shs	1.21 million shs
HRMY Harmony Biosciences	$34.38 +1.0%	$31.54	$26.47 ▼ $41.61	$1.97B	0.82	606,295 shs	531,767 shs
KNSA Kiniksa Pharmaceuticals	$27.43 +0.9%	$23.62	$17.38 ▼ $28.56	$2.00B	0.07	490,112 shs	543,644 shs
STOK Stoke Therapeutics	$9.61 -1.2%	$8.39	$5.35 ▼ $17.58	$524.68M	1.2	700,372 shs	375,650 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	0.00%	-1.79%	-19.83%	-13.29%	-28.99%
HRMY Harmony Biosciences	0.00%	+0.61%	+13.39%	+6.84%	+16.94%
KNSA Kiniksa Pharmaceuticals	0.00%	+2.01%	-0.80%	+27.82%	+44.29%
STOK Stoke Therapeutics	0.00%	+2.67%	-0.21%	+29.86%	-34.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNLI Denali Therapeutics	4.3504 of 5 stars	4.5	1.0	4.7	3.0	2.5	0.0
HRMY Harmony Biosciences	4.941 of 5 stars	4.6	4.0	0.0	3.6	3.3	4.4
KNSA Kiniksa Pharmaceuticals	2.7864 of 5 stars	3.5	2.0	0.0	2.7	3.3	0.6
STOK Stoke Therapeutics	4.0807 of 5 stars	3.6	2.0	4.8	3.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	3.06	Buy	$33.71	155.80% Upside
HRMY Harmony Biosciences	3.11	Buy	$52.78	53.51% Upside
KNSA Kiniksa Pharmaceuticals	3.00	Buy	$38.80	41.45% Upside
STOK Stoke Therapeutics	3.29	Buy	$23.20	141.42% Upside

Current Analyst Ratings Breakdown

Latest STOK, KNSA, HRMY, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
4/29/2025	KNSA Kiniksa Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	5.79	N/A	N/A	$7.42 per share	1.78
HRMY Harmony Biosciences	$744.85M	2.65	$2.57 per share	13.38	$7.97 per share	4.31
KNSA Kiniksa Pharmaceuticals	$481.17M	4.16	N/A	N/A	$6.23 per share	4.40
STOK Stoke Therapeutics	$190.91M	2.75	N/A	N/A	$3.57 per share	2.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$145.22M	-$2.67	N/A	N/A	N/A	N/A	-32.94%	-30.04%	7/31/2025 (Estimated)
HRMY Harmony Biosciences	$128.85M	$2.62	16.29	11.05	0.47	17.98%	23.16%	14.24%	8/5/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals	$14.08M	-$0.25	N/A	109.72	N/A	-2.36%	-7.31%	-5.95%	7/22/2025 (Estimated)
STOK Stoke Therapeutics	-$104.70M	$0.79	N/A	N/A	N/A	-629.90%	-54.45%	-40.77%	8/5/2025 (Estimated)

Latest STOK, KNSA, HRMY, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million
3/24/2025	Q4 2024	STOK Stoke Therapeutics	-$0.56	-$0.18	+$0.38	-$0.18	$4.20 million	$22.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	N/A	9.98	9.98
HRMY Harmony Biosciences	0.28	3.24	3.20
KNSA Kiniksa Pharmaceuticals	N/A	3.24	2.95
STOK Stoke Therapeutics	N/A	5.09	5.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
HRMY Harmony Biosciences	86.23%
KNSA Kiniksa Pharmaceuticals	53.95%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	12.50%
HRMY Harmony Biosciences	23.60%
KNSA Kiniksa Pharmaceuticals	54.57%
STOK Stoke Therapeutics	11.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	145.28 million	132.55 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	39.47 million	Optionable
KNSA Kiniksa Pharmaceuticals	220	72.97 million	32.80 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	46.98 million	Optionable

STOK, KNSA, HRMY, and DNLI Headlines

Recent News About These Companies

Financial Review: Renovaro (NASDAQ:RENB) & Stoke Therapeutics (NASDAQ:STOK)

June 2 at 2:25 AM | americanbankingnews.com

Voloridge Investment Management LLC Sells 36,261 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 31 at 3:56 AM | marketbeat.com

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2025 | businesswire.com

D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 29, 2025 | marketbeat.com

Toronto Dominion Bank Invests $35 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 28, 2025 | marketbeat.com

Biogen maps out $1B biobucks deal with RNAi-focused City Therapeutics

May 27, 2025 | fiercebiotech.com

Deutsche Bank AG Reduces Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 22, 2025 | marketbeat.com

Toronto Dominion Bank Acquires New Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 21, 2025 | marketbeat.com

Tang Capital Management LLC Buys Shares of 300,000 Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 20, 2025 | marketbeat.com

Chardan Capital Has Strong Forecast for STOK FY2025 Earnings

May 20, 2025 | marketbeat.com

RTW Investments LP Has $56.51 Million Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 18, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Cantor Fitzgerald

May 17, 2025 | marketbeat.com

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

May 16, 2025 | zacks.com

MPM Bioimpact LLC Has $7.57 Million Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 16, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up Following Earnings Beat

May 15, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

May 13, 2025 | zacks.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by Dimensional Fund Advisors LP

May 13, 2025 | marketbeat.com

Granahan Investment Management LLC Trims Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 12, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Brokerages

May 12, 2025 | marketbeat.com

DAFNA Capital Management LLC Has $1.89 Million Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 10, 2025 | marketbeat.com

Baker BROS. Advisors LP Increases Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, KNSA, HRMY, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$13.18 -0.36 (-2.66%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$13.24 +0.06 (+0.46%)

As of 04:01 AM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Harmony Biosciences NASDAQ:HRMY

$34.38 +0.33 (+0.97%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$34.50 +0.12 (+0.35%)

As of 04:01 AM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Kiniksa Pharmaceuticals NASDAQ:KNSA

$27.43 +0.25 (+0.92%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$27.36 -0.07 (-0.26%)

As of 04:00 AM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Stoke Therapeutics NASDAQ:STOK

$9.61 -0.12 (-1.23%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$9.54 -0.07 (-0.73%)

As of 03:59 AM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time